Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Infectious Diseases and Therapy
Published in: Infectious Diseases and Therapy 3/2024

Open Access 09-03-2024 | Urinary Tract Infection | Original Research

Clinical Characteristics of Uncomplicated Acute Pyelonephritis Caused by Escherichia coli and Klebsiella pneumoniae

Authors: Miri Hyun, Ji Yeon Lee, Kyong Ree Lim, Hyun ah Kim

Published in: Infectious Diseases and Therapy | Issue 3/2024

Login to get access

Abstract

Introduction

This study compared the clinical characteristics and antimicrobial susceptibility of uncomplicated acute pyelonephritis (APN) caused by Escherichia coli and Klebsiella pneumoniae.

Methods

We retrospectively reviewed the medical records of patients with uncomplicated APNs caused by E. coli and K. pneumoniae admitted to Keimyung University Dongsan Hospital between February 2014 and December 2021.

Results

We enrolled 497 patients (372 with E. coli infection, 125 with K. pneumoniae infection). Male, healthcare-associated infection, solid tumors, liver cirrhosis, chronic renal disease, solid organ transplantation, and antibiotic usage within the last 3 months were more strongly associated with K. pneumoniae uncomplicated APNs than with E. coli. Bacteremia and fever occurred more frequently in E. coli uncomplicated APNs. Antimicrobial resistance rates to piperacillin/tazobactam and carbapenem were higher in K. pneumoniae. Antimicrobial resistance rates to aztreonam and ciprofloxacin were lower in K. pneumoniae. Thirty-day mortality was more observed in K. pneumoniae group in univariate analysis, but this difference was not observed after adjustment. Male sex, ultimately fatal disease in McCabe, and prior antibiotic use within 3 months were more associated with K. pneumoniae.

Conclusions

Male, underlying diseases, and prior antibiotic use was more associated with K. pneumoniae. Further study will be needed that microbiome of each situation and the related with the distribution of the strains.
Appendix
Available only for authorised users
Literature
1.
Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol. 2015;13:269–84.PubMedCrossRefPubMedCentral
2.
Kang CI, Chung DR, Son JS, et al. Clinical significance of nosocomial acquisition in urinary tract-related bacteremia caused by gram-negative bacilli. Am J Infect Control. 2011;39:135–40.PubMedCrossRef
3.
Russo TA, Johnson JR. Proposal for a new inclusive designation for extraintestinal pathogenic isolates of Escherichia coli: ExPEC. J Infect Dis. 2000;181:1753–4.PubMedCrossRef
4.
Bien J, Sokolova O, Bozko P. Role of uropathogenic Escherichia coli virulence factors in development of urinary tract infection and kidney damage. Int J Nephrol. 2012;2012: 681473.PubMedCrossRefPubMedCentral
5.
Doumith M, Day MJ, Hope R, Wain J, Woodford N. Improved multiplex PCR strategy for rapid assignment of the four major Escherichia coli phylogenetic groups. J Clin Microbiol. 2012;50:3108–10.PubMedCrossRefPubMedCentral
6.
Staji H, Rassouli M, Jourablou S. Comparative virulotyping and phylogenomics of Escherichia coli isolates from urine samples of men and women suffering urinary tract infections. Iran J Basic Med Sci. 2019;22:211–4.PubMedPubMedCentral
7.
8.
Hyun M, Lee JY, Ryu SY, Ryoo N, Kim HA. Antibiotic resistance and clinical presentation of health care-associated hypervirulent Klebsiella pneumoniae infection in Korea. Microb Drug Resist. 2019;25:1204–9.PubMedCrossRef
9.
Liu Y, Du FL, Xiang TX, et al. High prevalence of plasmid-mediated quinolone resistance determinants among serotype K1 hypervirulent Klebsiella pneumoniae Isolates in China. Microb Drug Resist. 2019;25:681–9.PubMedCrossRef
10.
Shen D, Ma G, Li C, et al. Emergence of a multidrug-resistant hypervirulent Klebsiella pneumoniae sequence type 23 strain with a rare bla CTX-M-24-harboring virulence plasmid. Antimicrob Agents Chemother 2019;63:e02273–18.
11.
Yang YS, Ku CH, Lin JC, et al. Impact of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae on the outcome of community-onset bacteremic urinary tract infections. J Microbiol Immunol Infect. 2010;43:194–9.PubMedCrossRef
12.
Kayaaslan B, Oktay Z, Hasanoglu I, et al. Increasing rates of extended-spectrum B-lactamase-producing Escherichia coli and Klebsiella pneumoniae in uncomplicated and complicated acute pyelonephritis and evaluation of empirical treatments based on culture results. Eur J Clin Microbiol Infect Dis. 2022;41:421–30.PubMedCrossRef
13.
Ranjan Dash N, Albataineh MT, Alhourani N, et al. Community-acquired urinary tract infections due to extended-spectrum beta-lactamase-producing organisms in United Arab Emirates. Travel Med Infect Dis. 2018;22:46–50.PubMedCrossRef
14.
Richelsen R, Smit J, Schonheyder HC, et al. Outcome of community-onset ESBL-producing Escherichia coli and Klebsiella pneumoniae bacteraemia and urinary tract infection: a population-based cohort study in Denmark. J Antimicrob Chemother. 2020;75:3656–64.PubMedCrossRef
15.
Hyun M, Lee JY, Kim HA, Ryu SY. Comparison of Escherichia coli and Klebsiella pneumoniae acute pyelonephritis in Korean patients. Infect Chemother. 2019;51:130–41.PubMedCrossRefPubMedCentral
16.
Kunin CM. Definition of acute pyelonephritis vs the urosepsis syndrome. Arch Intern Med. 2003;163:2393 (author reply 2393-2394).PubMedCrossRef
17.
Murray BO, Flores C, Williams C, et al. Recurrent urinary tract infection: a mystery in search of better model systems. Front Cell Infect Microbiol. 2021;11: 691210.PubMedCrossRefPubMedCentral
18.
Makris K, Spanou L. Acute kidney injury: definition, pathophysiology and clinical phenotypes. Clin Biochem Rev. 2016;37:85–98.PubMedPubMedCentral
19.
McCabe WR, Jackson GG. Gram-negative bacteremia. 1. Etiology and ecology. Arch Intern Med. 1962;110:847–55.CrossRef
20.
Korvick JA, Bryan CS, Farber B, et al. Prospective observational study of Klebsiella bacteremia in 230 patients: outcome for antibiotic combinations versus monotherapy. Antimicrob Agents Chemother. 1992;36:2639–44.PubMedCrossRefPubMedCentral
21.
Paterson DL, Ko WC, Von Gottberg A, et al. International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial Infections. Ann Intern Med. 2004;140:26–32.PubMedCrossRef
22.
Ioannou P, Plexousaki M, Dimogerontas K, et al. Characteristics of urinary tract infections in older patients in a tertiary hospital in Greece. Geriatr Gerontol Int. 2020;20:1228–33.PubMedCrossRef
23.
Mouanga Ndzime Y, Onanga R, Kassa Kassa RF, et al. Epidemiology of community origin Escherichia coli and Klebsiella pneumoniae uropathogenic strains resistant to antibiotics in Franceville. Gabon Infect Drug Resist. 2021;14:585–94.PubMedCrossRef
24.
Behzadi P, Behzadi E, Yazdanbod H, Aghapour R, Akbari Cheshmeh M, Salehian OD. A survey on urinary tract infections associated with the three most common uropathogenic bacteria. Maedica (Bucur). 2010;5:111–5.PubMed
25.
Fabbian F, De Giorgi A, Lopez-Soto PJ, et al. Is female gender as harmful as bacteria? Analysis of hospital admissions for urinary tract infections in elderly patients. J Womens Health (Larchmt). 2015;24:587–92.PubMedCrossRef
26.
27.
28.
29.
Hreha TN, Collins CA, Daugherty AL, Griffith JM, Hruska KA, Hunstad DA. Androgen-influenced polarization of activin A-producing macrophages accompanies post-pyelonephritic renal scarring. Front Immunol. 2020;11:1641.PubMedCrossRefPubMedCentral
30.
Ashour HM, El-Sharif A. Species distribution and antimicrobial susceptibility of gram-negative aerobic bacteria in hospitalized cancer patients. J Transl Med. 2009;7:14.PubMedCrossRefPubMedCentral
31.
Mitsuboshi A, Kishimoto K, Ito Y, et al. Incidence and causative organisms of bacteriuria in children with cancer: a 9-year experience in a tertiary pediatric center. J Pediatr Hematol Oncol. 2023;45:21–4.PubMedCrossRef
32.
Ikeda M, Mizoguchi M, Oshida Y, et al. Clinical and microbiological characteristics and occurrence of Klebsiella pneumoniae infection in Japan. Int J Gen Med. 2018;11:293–9.PubMedCrossRefPubMedCentral
33.
Talukdar A, Barman R, Sarma A, et al. Bacteriological profile and antibiotic sensitivity pattern of clinical isolates in a tertiary cancer care center in the Northeast India. South Asian J Cancer. 2020;9:115–9.PubMedCrossRefPubMedCentral
34.
An J, Kim JB, Yang EY, et al. Bacterial extracellular vesicles affect endocrine therapy in MCF7 cells. Medicine (Baltimore). 2021;100: e25835.PubMedCrossRef
35.
Bhattacharya C, Das-Mondal M, Gupta D, Sarkar AK, Kar-Purkayastha S, Konar A. Infection in cirrhosis: a prospective study. Ann Hepatol. 2019;18:862–8.PubMedCrossRef
36.
Ham SY, Jung H, Song KH, et al. Interspecies differences in clinical characteristics and risk factors for third-generation cephalosporin resistance between Escherichia coli and Klebsiella pneumoniae bloodstream infection in patients with liver cirrhosis. Eur J Clin Microbiol Infect Dis. 2022;41:1459–65.PubMedCrossRef
37.
Lee CI, Lee NY, Yan JJ, et al. Extended-spectrum beta-lactamase-producing phenotype signifies a poor prognosis for patients with cefpodoxime-resistant Escherichia coli or Klebsiella pneumoniae bacteremia. J Microbiol Immunol Infect. 2009;42:303–9.PubMed
38.
39.
Alangaden GJ, Thyagarajan R, Gruber SA, et al. Infectious complications after kidney transplantation: current epidemiology and associated risk factors. Clin Transplant. 2006;20:401–9.PubMedCrossRef
40.
Freire MP, Mendes CV, Piovesan AC, et al. Does the urinary tract infection caused by carbapenem-resistant Gram-negative bacilli impact the outcome of kidney transplant recipients? Transpl Infect Dis. 2018;20: e12923.PubMedCrossRef
41.
Goldman JD, Julian K. Urinary tract infections in solid organ transplant recipients: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33: e13507.PubMedCrossRef
42.
Krawczyk B, Wysocka M, Michalik M, Golebiewska J. Urinary tract infections caused by K. pneumoniae in kidney transplant recipients-epidemiology, virulence and antibiotic resistance. Front Cell Infect Microbiol. 2022;12:861374.PubMedCrossRefPubMedCentral
43.
Struve C, Bojer M, Krogfelt KA. Identification of a conserved chromosomal region encoding Klebsiella pneumoniae type 1 and type 3 fimbriae and assessment of the role of fimbriae in pathogenicity. Infect Immun. 2009;77:5016–24.PubMedCrossRefPubMedCentral
44.
45.
Hugenholtz F, van der Veer C, Terpstra ML, et al. Urine and vaginal microbiota compositions of postmenopausal and premenopausal women differ regardless of recurrent urinary tract infection and renal transplant status. Sci Rep. 2022;12:2698.PubMedCrossRefPubMedCentral
46.
Vachvanichsanong P, McNeil EB, Dissaneewate P. Extended-spectrum beta-lactamase Escherichia coli and Klebsiella pneumoniae urinary tract infections. Epidemiol Infect. 2020;149: e12.PubMedCrossRefPubMedCentral
47.
Shigemura K, Kitagawa K, Nomi M, Yanagiuchi A, Sengoku A, Fujisawa M. Risk factors for febrile genito-urinary infection in the catheterized patients by with spinal cord injury-associated chronic neurogenic lower urinary tract dysfunction evaluated by urodynamic study and cystography: a retrospective study. World J Urol. 2020;38:733–40.PubMedCrossRef
48.
Mukai S, Shigemura K, Nomi M, et al. Retrospective study for risk factors for febrile UTI in spinal cord injury patients with routine concomitant intermittent catheterization in outpatient settings. Spinal Cord. 2016;54:69–72.PubMedCrossRef
49.
50.
Reuschel E, Toelge M, Entleutner K, Deml L, Seelbach-Goebel B. Cytokine profiles of umbilical cord blood mononuclear cells upon in vitro stimulation with lipopolysaccharides of different vaginal gram-negative bacteria. PLoS ONE. 2019;14: e0222465.PubMedCrossRefPubMedCentral
51.
Wright KJ, Seed PC, Hultgren SJ. Development of intracellular bacterial communities of uropathogenic Escherichia coli depends on type 1 pili. Cell Microbiol. 2007;9:2230–41.PubMedCrossRef
52.
53.
Ciesielczuk H, Betts J, Phee L, et al. Comparative virulence of urinary and bloodstream isolates of extra-intestinal pathogenic Escherichia coli in a Galleria mellonella model. Virulence. 2015;6:145–51.PubMedCrossRefPubMedCentral
54.
Choi MH, Kim D, Park Y, Jeong SH. Impact of urinary tract infection-causative microorganisms on the progression to bloodstream infection: a propensity score-matched analysis. J Infect. 2022;85:513–8.PubMedCrossRef
55.
Jalil MB, Al Atbee MYN. The prevalence of multiple drug resistance Escherichia coli and Klebsiella pneumoniae isolated from patients with urinary tract infections. J Clin Lab Anal. 2022;36: e24619.PubMedCrossRefPubMedCentral
56.
Kim B, Kim J, Jo HU, et al. Changes in the characteristics of community-onset fluoroquinolone-resistant Escherichia coli isolates causing community-acquired acute pyelonephritis in South Korea. J Microbiol Immunol Infect. 2022;55:678–85.PubMedCrossRef
57.
Vuotto C, Longo F, Pascolini C, et al. Biofilm formation and antibiotic resistance in Klebsiella pneumoniae urinary strains. J Appl Microbiol. 2017;123:1003–18.PubMedCrossRef
58.
Kurowski KM, Marusinec R, Amato HK, et al. Social and environmental determinants of community-acquired antimicrobial-resistant Escherichia coli in children living in semirural communities of Quito, Ecuador. Am J Trop Med Hyg. 2021;105:600–10.PubMedCrossRefPubMedCentral
59.
Torres E, Lopez-Cerero L, Morales I, Navarro MD, Rodriguez-Bano J, Pascual A. Prevalence and transmission dynamics of Escherichia coli ST131 among contacts of infected community and hospitalized patients. Clin Microbiol Infect. 2018;24:618–23.PubMedCrossRef
60.
61.
Metadata
Title
Clinical Characteristics of Uncomplicated Acute Pyelonephritis Caused by Escherichia coli and Klebsiella pneumoniae
Authors
Miri Hyun
Ji Yeon Lee
Kyong Ree Lim
Hyun ah Kim
Publication date
09-03-2024
Publisher
Springer Healthcare
Published in
Infectious Diseases and Therapy / Issue 3/2024
Print ISSN: 2193-8229
Electronic ISSN: 2193-6382
DOI
https://doi.org/10.1007/s40121-024-00940-3

Other articles of this Issue 3/2024

Infectious Diseases and Therapy 3/2024 Go to the issue

Original Research

Cost of Illness Analysis of Invasive Meningococcal Disease Caused by Neisseria Meningitidis Serogroup B in the Netherlands—a Holistic Approach

Original Research

Dalbavancin Sequential Therapy for Gram-Positive Bloodstream Infection: A Multicenter Observational Study

Original Research

Oritavancin Versus Daptomycin for Osteomyelitis Treatment After Surgical Debridement

Commentary

Living During COVID-19 While Immunocompromised: A Patient and Physician Perspective from France

Publisher Correction

Publisher Correction: Podcast: Influenza-Associated Complications and the Impact of Vaccination on Public Health

Original Research

Estimated Respiratory Syncytial Virus-Related Hospitalizations and Deaths Among Children and Adults in Spain, 2016–2019
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits